Get the Stockscreener App
15.21
3.80%
-0.60
Assembly Biosciences Inc stock is traded at $15.21, with a volume of 30,654.
It is down -3.80% in the last 24 hours and up +1.26% over the past month.
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two innovative platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.
See More
Previous Close:
$15.81
Open:
$15.7
24h Volume:
30,654
Relative Volume:
0.87
Market Cap:
$96.68M
Revenue:
-
Net Income/Loss:
$-61.23M
P/E Ratio:
-9.3313
EPS:
-1.63
Net Cash Flow:
$22.49M
1W Performance:
-1.11%
1M Performance:
+1.26%
6M Performance:
-0.59%
1Y Performance:
+64.61%
1-Day Range:
$15.00
$16.26
1-Week Range:
$13.20
$16.75
52-Week Range:
$9.1032
$19.93
Assembly Biosciences Inc Stock (ASMB) Company Profile
Name
Assembly Biosciences Inc
Sector
Industry
Phone
(833) 409-4583
Address
TWO TOWER PLACE, SOUTH SAN FRANCISCO
Compare ASMB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ASMB
Assembly Biosciences Inc
|
15.21 | 96.68M | 0 | -61.23M | 22.49M | -13.52 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Assembly Biosciences Inc Stock (ASMB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-20-24 | Upgrade | Jefferies | Hold → Buy |
| Sep-13-21 | Initiated | H.C. Wainwright | Neutral |
| Sep-02-21 | Downgrade | William Blair | Outperform → Mkt Perform |
| Mar-23-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Nov-06-20 | Downgrade | Jefferies | Buy → Hold |
| Oct-19-20 | Initiated | Truist | Buy |
| Oct-16-19 | Initiated | Mizuho | Buy |
| Nov-19-18 | Initiated | Leerink Partners | Outperform |
| Oct-08-18 | Upgrade | B. Riley FBR | Neutral → Buy |
| Aug-08-18 | Initiated | Robert W. Baird | Outperform |
| Apr-13-18 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Jan-05-18 | Initiated | B. Riley FBR, Inc. | Neutral |
| Nov-08-17 | Initiated | Jefferies | Buy |
| May-30-17 | Initiated | Chardan Capital Markets | Buy |
View All
Assembly Biosciences Inc Stock (ASMB) Latest News
Assembly Biosciences (NASDAQ:ASMB) Stock Price Crosses Above Two Hundred Day Moving Average – Here’s What Happened - Defense World
Gilead raises Assembly Bio stake to ~30% - MSN
Gilead invests in Assembly Bio to advance clinical programs - The Pharma Letter
Gilead boosts stake in Assembly Bio with $30.1 million investment By Investing.com - Investing.com Canada
Assembly Biosciences strikes amended deal with Gilead - Investing.com
Assembly Biosciences strikes amended deal with Gilead By Investing.com - Investing.com UK
Assembly Bio stock rises as Gilead ups stake (ASMB:NASDAQ) - Seeking Alpha
Assembly Biosciences Shares Rise 19% After Gilead Investment, Funding - MarketWatch
Assembly Biosciences Gets $30.1M Equity Investment, Funding From Gilead - MarketWatch
Assembly Biosciences Announces $30.1 Million Equity Investment and Accelerated Funding from Gilead to Advance Clinical Development Programs - The Manila Times
Assembly Biosciences Announces $30.1 Million Equity Investment and Accelerated Funding from - The Bakersfield Californian
Assembly Bio Secures $30.1M Gilead Investment, Advancing Ambitious Antiviral Pipeline - StockTitan
(ASMB) Trading Advice - Stock Traders Daily
Assembly Biosciences, Inc. (NASDAQ:ASMB) Sees Significant Growth in Short Interest - MarketBeat
Reviewing BeiGene (NASDAQ:BGNE) and I-Mab (NASDAQ:IMAB) - Defense World
How the (ASMB) price action is used to our Advantage - Stock Traders Daily
Assembly Biosciences, Inc. (NASDAQ:ASMB) Sees Large Increase in Short Interest - MarketBeat
Assembly Biosciences investor Alexander Schornstein buys $372,994 in shares By Investing.com - Investing.com
Novavax and Assembly lead infectious disease gainers in 2024 - BioWorld Online
Comparing Cardiol Therapeutics (NASDAQ:CRDL) & Gilead Sciences (NASDAQ:GILD) - Defense World
Genome Editing Market Size Projected to Reach USD 32.72 - GlobeNewswire
Assembly Biosciences Reports Q3 2024 Financials and Strategic Advances - TipRanks
(ASMB) Pivots Trading Plans and Risk Controls - Stock Traders Daily
ARMISTICE CAPITAL, LLC Adjusts Stake in Assembly Biosciences Inc - GuruFocus.com
HC Wainwright Has Optimistic Outlook of ASMB FY2024 Earnings - MarketBeat
Assembly Biosciences, Inc. (NASDAQ:ASMB) Short Interest Down 51.2% in October - MarketBeat
Analysts Just Slashed Their Assembly Biosciences, Inc. (NASDAQ:ASMB) EPS Numbers - Simply Wall St
Bearish: Analysts Just Cut Their Assembly Biosciences, Inc. (NASDAQ:ASMB) Revenue and EPS estimates - Yahoo Finance
Analyzing Taysha Gene Therapies (NASDAQ:TSHA) & Gilead Sciences (NASDAQ:GILD) - Defense World
Assembly Biosciences: Q3 Earnings Snapshot - CTPost
Assembly Biosciences Reports Third Quarter 2024 Financial Results and Recent Updates - The Manila Times
Assembly Biosciences initiates at-the-market equity program - Investing.com India
Assembly Biosciences Inc (ASMB) Reports Q3 2024 Revenue of $6.8M, GAAP EPS Loss of $1.51, Misses Estimates - GuruFocus.com
Marquis Who's Who Honors Jonathan Colon, PhD, for Expertise in Biotechnology - 24-7 Press Release
Assembly Biosciences (NASDAQ:ASMB) Stock Crosses Above 200-Day Moving AverageShould You Sell? - MarketBeat
When (ASMB) Moves Investors should Listen - Stock Traders Daily
Baker Lab’s AI-Driven Antibody Cage Technology Unlocked as Archon Biosciences - Genetic Engineering & Biotechnology News
Short Interest in Assembly Biosciences, Inc. (NASDAQ:ASMB) Declines By 7.9% - MarketBeat
Assembly Biosciences (NASDAQ:ASMB) Share Price Crosses Above 200 Day Moving AverageHere's Why - MarketBeat
(ASMB) Investment Analysis and Advice - Stock Traders Daily
Microbiome Manufacturing Market Poised for Robust Growth at 15.4% CAGR by 2031 - WhaTech
Assembly Biosciences (NASDAQ:ASMB) Shares Pass Above 200-Day Moving AverageTime to Sell? - MarketBeat
Assembly Biosciences, Inc. (NASDAQ:ASMB) Short Interest Update - MarketBeat
Assembly Biosciences, Inc.'s (NASDAQ:ASMB) market cap surged US$16m last week, individual investors who have a lot riding on the company were rewarded - Simply Wall St
Assembly Biosciences sees major stock purchase by investor Alexander Schornstein By Investing.com - Investing.com Canada
Alexander Schornstein Purchases 10,000 Shares of Assembly Biosciences, Inc. (NASDAQ:ASMB) Stock - MarketBeat
Assembly Biosciences (NASDAQ:ASMB) Share Price Crosses Above 200-Day Moving AverageTime to Sell? - MarketBeat
Assembly Biosciences CEO sells shares worth $2,917 to cover taxes By Investing.com - Investing.com South Africa
Assembly Biosciences Inc Stock (ASMB) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):